Kornimate/medical-research-clean huggingface dataset:
walking gait biomechanics following knee joint effusion

Conditions: Knee Injuries; Knee Osteoarthritis

Summary: the purpose of this study is to determine the sensitivity of a wearable sensor to detect changes in knee joint loading using an experimental knee joint effusion as a model for a common clinical physiological alteration in joint status. the rationale for this project is that it will establish the efficacy of an inexpensive, clinically, and publicly available device that can detect changes in biomechanical loading due to acute physiologic change in joint status. the study will utilize a cross-sectional cohort study design and will seek to enroll 25 male and female healthy adult participants (18-35 yo). participants will report to the laboratory for three total sessions (session 1: informed consent and task familiarization; session 2: testing; session 3: knee joint status assessment). the primary outcomes of interest include lower extremity thigh and shank acceleration and velocity data (wearable sensor data), lower extermity 3d kinematics and kinetics (motion capture data), and lower extremity muscle function (emg data) during walking gait, as well as functional balance and patient-reported subjective outcomes. data will be analyzed by calculating change scores from the pre- to post-experimental effusion outcome measure testing. paired-samples t-tests and cohen's d effect sizes will be used to assess changed in wearable sensor data from pre- to post-experimental effusion. correlation statistics will be used to determine if there are association between the motion capture and wearable sensor data. the potential risks associated with an experimental joint effusion will be addressed by maintaining appropriate sterile conditions and having the participant check-in with the pi (licensed healthcare provider) at 48 hours following testing session.


Eligibility criteria:
inclusion criteria: * male and female * chronological age 18-35 at the time of study participation * physically active (at least 30 minutes of physical activity, 3x/week) * tegner activity scale score at least 5/10 exclusion criteria: * history of lower extremity or lumbar spine surgery. * history of lower extremity or lumbar spine injury in the prior 6 months. * history of major ligamentous damage. * current knee pain. * known neurological condition, autoimmune condition, cardiovascular disease. * history of epilepsy, seizures, concussion within the prior 6 months. * currently taking pain altering medication. * fear of needles * unable to read and understand english language * pregnancy

Keywords: biomechanics inertial measurement unit
musical biofeedback for sensorimotor control capacity of hands

Conditions: Hand Injuries

Summary: in the proposed study, the investigators assumed that music support treatment, a multisensory-based framework for ameliorating brain plasticity, combined with low-amplitude vibration stimulation can prime motor system and change in motor performance for the patient with a peripheral injury or the loss of a limb. the specific aim of this study is to develop a multisensory biofeedback with musical interface system, with the aim of improving the sensorimotor impairment of patients' hands.the expected outcomes of this research are to clarify the effects of application multisensory biofeedback with musical interface on motor and hand function for patients with hand injuries.


Eligibility criteria:
inclusion criteria: * tendon and bone injury in hand, wrist, and forearm; peripheral nerve injury in upper extremity; replantation; a combination of nerve and tendon or vascular injury; the protective sensation of the hand is absent or impaired exclusion criteria: * patients with deficits in cognition, perception or language comprehension, as well as severe pain and swelling in the upper limbs

Keywords: musical biofeedback auditory vibrotactile stimulation
gastric accommodation and gastroesophageal reflux

Conditions: Gastroesophageal Reflux Disease

Summary: gastroesophageal reflux events generally happen during relaxation of lower esophageal sphincter. this relaxation is a reflex that is triggered by gastric stimuli. the investigators hypothesize that abnormal relaxation of the gastric wall after a meal may lead to reflux events. to test this hypothesis, a study was designed to measure the gastric accommodation in patients undergoing esophageal impedance monitoring.

gastroesophageal reflux events happen during relaxations of lower esophageal sphincter not related to swallowing, called transient. these transient lower esophageal sphincter relaxations (tlesr) are generally triggered by gastric distension and its physiological purpose is to vent the stomach. the gastric accommodation is a physiological process in which the gastric fundus actively relaxes during a meal in order to accommodate it. this study is driven by the hypothesis that impairment of the gastric accommodation may facilitate triggering tlesr and, therefore, reflux events. we aim to evaluate the relation between gastric fundic relaxation and the number of gastroesophageal reflux events in children. we also aim to evaluate if there is a relation between the gastric emptying and the number of reflux episodes.

Eligibility criteria:
inclusion criteria: * children and adolescents older than 1-year old who were referred for combined esophageal impedance ph monitoring for gerd\* symptoms exclusion criteria: * continuous feeding * previous fundoplication

Keywords: gastroesophageal reflux disease, gastric motility
adoptive cellular therapy and radiation therapy after surgery in treating patients with esophageal cancer

Conditions: Esophageal Cancer

Summary: cytokine-induced killer (cik) cells show cytolytic activity against tumor. radiation therapy uses high-energy x-rays to damage tumor cells. combining radiation therapy with adoptive cellular therapy after surgery may be more effective than uses radiation therapy alone in treating esophageal cancer.


Eligibility criteria:
inclusion criteria: * cytologically or histologically confirmed esophageal carcinoma * tumor extension beyond muscularis propria and/or nodal involvement without evidence of m1 disease * prior en bloc resection, with curative intent, of all known tumor * no metastatic disease * age: \> 18 * karnofsky performance status ≥ 70 * at least 3 weeks since prior surgery * normal functions of heart, lung, liver, kidney and bone marrow * blood exams qualified for chemotherapy, which included hemoglobulin ≥9 g/dl, neutrophil ≥1.5×109/l and platelet (plt) ≥100×109/l, creatinine ≤1.5 unl * all patients must be evaluated by a radiation oncologist prior to enrollment to ensure patient is appropriate for radiotherapy * informed consent signed exclusion criteria: * patients with metastatic disease. * patients who are pregnant or nursing. * patients with poor bone marrow, liver and kidney functions, which would make radiation therapy intolerable * patients with contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or haematemesis

Keywords: esophageal cancer dc-cik immunotherapy cellular therapy radiation therapy
the role of rosuvastatin on vascular involvement in behçet's disease

Conditions: Behcet's Disease

Summary: behçet's disease(bd) is a systemic inflammatory vasculitis, which affects all types and sizes of vessels. statins display numerous effects often independent of the well-established lipid-lowering effects that may be of benefit in retarding or preventing vascular injury and ischaemic vascular events. the aim of the present study was to determine the efficacy of rosuvastatin in improving vascular dysfunction and vascular inflammation and to assess the effect of rosuvastatin on vascular involvement in bd patients. fifty-six bd patients (51 males and 5 females) mean age 33.4 years, mean disease duration 5.8 years), all fulfilling the classification criteria of the international study group for behçet's disease were recruited.patients were randomised into 2 groups. the first group (n=27: 20 active and 7 inactive) were assigned to receive 40 mg of rosuvastatin and the second group(n=29: 21 active and 8 inactive) received placebo for 12 months. inflammatory and endothelial dysregulation markers were measured at baseline and after 12 months. all patients were examined for vascular involvement. venous or arterial system involvement was defined as present when confirmed by doppler ultrasonography, magnetic resonance angiography, conventional angiography or ct.


Eligibility criteria:
inclusion criteria: * all patients fulfilling the classification criteria of the international study group for behçet's disease exclusion criteria: * smoking, * diabetes mellitus, * hypercholesterolaemia, * hypertension, * cardiac insufficiency, * coexisting hepatic and renal diseases * inflammatory diseases.

Keywords: behcet's disease rosuvastatin vascular markers improvement in vascular involvement in behcet's disease
evaluation of the discriminative abilities of biomarkers for the diagnosis of acute mesenteric ischemia compared with another similar clinical presentation: a pilot study

Conditions: Acute Mesenteric Ischemia

Summary: acute mesenteric ischemia (ami) is associated with high mortality (50-80%). the prognosis depends on the time it takes to diagnose the condition, and the possibility of revascularization in eligible patients. delayed diagnosis is due in particular to the aspecific clinical presentation and the absence of biomarkers to guide early diagnosis, lactates often being elevated at an already irreversible stage. adenosine deaminase is produced in the presence of ischemia (known from myocardial ischemia), and is present on the surface of intestinal villi. the investigator's hypothesis is that, in the event of digestive ischemia resulting in abnormalities of mesenteric permeability, adenosine deaminase will enter the bloodstream and increase its soluble plasma activity, along with an increase in lymphocyte-bound adenosine deaminase. the main objective is to evaluate the discriminatory capacities of soluble adenosine deaminase, collected via blood sampling, for the diagnosis of ima in comparison with the reference method (injected abdominopelvic ct scan), performed for abdominal pain suggestive of ima. the study will be based on a prospective monocentric cohort. currently, there is no specific biological marker for ima, and the gold standard for diagnosis is the injected abdominopelvic ct scan, performed for hyperintense abdominal pain. two groups will be identified on the basis of the gold-standard abdominopelvic scan: * the "ima patients" group: patients with hyperintense abdominal pain, and ima confirmed by ct scan * the "non-ima patients" group: patients with hyperintense abdominal pain, but with a diagnosis other than ima on the ct scan. 130 subjects will be included in this study inclusion period: 18 months follow-up period: 1 month analysis period: 5 months total duration: 24 months


Eligibility criteria:
inclusion criteria: * male or female, 18 years of age or older * with an indication (hyperintense abdominal pain with no obvious diagnosis other than acute mesenteric ischemia) for an injected abdominopelvic scan for hyperintense abdominal pain suspected of acute mesenteric ischemia * including pregnant or breast-feeding women, as this is a risk factor for ami in young subjects * affiliated with the french social security system * able to express non-opposition in writing exclusion criteria: * presenting acute myocardial ischemia, to avoid biasing the levels of the biomarkers studied (increased in this clinical situation) * patient in a period of exclusion from another research protocol at the time the non-opposition is signed, * person protected by articles l1121-6 and l1121-8 of the french public health code (deprived of liberty by court order, socially vulnerable, adult incapable or unable to express non-opposition). * persons who are unable to read and understand the french language sufficiently to give their consent to participate in research.
the effect of perthes' disease on hip cartilage

Conditions: Perthes' Disease

Summary: the purpose of this study is to determine whether perthes' disease has caused detectable hip cartilage damage in young people who have reached the healed stage of the disease.

we will recruit 20 subjects from our healed perthes' population. we will use dgemric imaging to identify regions of cartilage degeneration in the femur and acetabulum. both hips will be imaged so that we can use the unaffected side as a control. we will apply dgemric imaging, which allows the composition of cartilage (specifically, the concentration of glycosaminoglycans \[gags\], important structural proteins in the cartilage) to be assessed. the mri protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[gd-dtpa2-\] contrast agent (magnevist, bayer) 90 minutes prior to imaging. due to the need to image within a relatively narrow window of time, each hip of each subject must be imaged on separate days. the subject will be asked to walk for 10 minutes after receiving the contrast agent injection to facilitate equilibration of contrast agent into the hip joint. the scans will be performed at ubc's high field imaging centre on the 3t phillips intera scanner. dr. wilson has access to this scanner for his research. the scanning protocol is as follows: 3d ir-tfe sequence with tr/te/flip of 4.7 ms/1.6 ms/30 o and seven inversion times; 1600, 1200, 800, 400, 200, 300, and 100 ms. in-plane resolution is 0.7 mm with a slice thickness of 3 mm. total imaging time is approximately 1 hour (at each visit). the t1 calculated image will be obtained using validated, custom written software (igor). the resulting image provides a map approximating glycosaminoglycan concentration and, consequently, cartilage degeneration. the mri will not be done under sedation. mris are performed under sedation at bcch for children under age seven. subjects in this study will be between the ages of 7 and 18. the contrast agent, gd-dtpa2- is routinely used in children in the clinical setting. radiographs used for comparison are obtained as part of standard of care follow-up protocol.

Eligibility criteria:
inclusion criteria: * subjects must have reached the healed stage of unilateral perthes' disease. -subjects will be between 7 and 18 years of age. * subjects must understand english. exclusion criteria: * subjects will be excluded if they have bilateral perthes' disease or if they have not yet reached the healing stage of the disease. * subjects will also be excluded if they do not meet the criteria to have an mri (e.g., the subject has metal implants, is claustrophobic, has a metallic object in eye or a pacemaker). * a subject will be excluded if they have any of the precautions for the mr contrast agent, magnevist, such as pregnancy, breast-feeding, respiratory allergies, asthma, thrombotic syndromes, history of grand mal seizures, impaired renal or hepatic function.

Keywords: mri perthes'disease hip cartilage
feasibility of combining family and cognitive therapy to prevent chronic anorexia

Conditions: Anorexia Nervosa

Summary: this study aims to investigate the feasibility of combining cognitive remediation therapy (crt) with family based treatment (fbt) for future use in a randomized clinical trial to reduce the risk of adolescents developing persistent anorexia nervosa. participants will be randomly assigned to one of two groups: one group will receive fbt and crt, and the other group will receive fbt and art therapy.


Eligibility criteria:
inclusion criteria: * meets dsm-iv criteria for anorexia nervosa lives with at least one english-speaking parent who is willing to participate medically stable endorses obsessions/compulsions adequate transportation to clinic proficient at speaking, reading, and writing english exclusion criteria: * previous fbt or crt for an medical instability medical condition that may affect eating or weight

Keywords: eating disorder anorexia nervosa eating disorder not otherwise specified maudsley family-based therapy fbt family therapy cognitive remediation therapy crt
florida cardiovascular quality network

Conditions: Stable Ischemic Heart Disease

Summary: florida cardiovascular quality network application of clinical decision support software tools at the point of care in patients with stable ischemic heart disease - a quality outcomes registry

the florida cardiovascular quality network (fcqn) is a quality outcomes registry. in a diverse group of clinical sites in florida, a large number of patients with known or possible stable ischemic cardiovascular disease (sihd) referred for cardiovascular stress test will be enrolled in this quality demonstration registry. this registry is based on the hypothesis that evidence-based clinical guidelines and appropriate use criteria (auc), when provided at the site and time of care (point of care), may improve physician clinical decisions and, thus, the overall quality and value of care for individual patients and populations. specifically, this study registry will utilize multiple proven software tools at the point of care: (1) seattle angina questionnaire (saq) as the method of measurement of patient angina symptoms; (2) focus, american college of cardiology (acc) software to provide clinical decision support (cds) as the primary method of determination of auc in patients with a clinical indication for a cardiovascular stress test; (3) cath/pci, acc / national cardiovascular data registry (ncdr) to provide clinical decision support as the primary method of determination of auc in the cardiac catheterization laboratory; (4) pinnacle, acc/ncdr clinical registry to provide an extensive database of clinical quality metrics; and (5) acc cardiosmart software modules as the primary patient education tool for effective risk factor modification. the application of these clinically proven software tools, all applied at the point of patient care, may assist physician compliance with acc guideline based auc and may directly result in an increase in sihd patients treated with guideline directed medical treatment as well as guideline directed interventional treatment. it is anticipated that this increased compliance with acc guidelines and auc may directly correlate with improved patient clinical outcomes.

Eligibility criteria:
inclusion criteria: 1. patient presents for evaluation of sihd and meets patient eligibility criteria as defined as sihd group a or sihd group b patient. 2. patient is over 21 years of age 3. patient is a stable clinic patient with the intention to continue in continuous medical care for the duration of the registry. exclusion criteria: 1. patient is diagnosed with acute coronary syndrome (unstable angina, myocardial infarction -either non-stemi or stemi) 2. patient has a concomitant medical illness that may limit survival to less than 1 year
quetiapine augmentation versus clomipramine augmentation of ssri for obsessive-compulsive disorder patients

Conditions: Obsessive Compulsive Disorder

Summary: the objective of this trial is to compare in an open trial format the efficacy of association of clomipramine and quetiapine with ssri after ssri treatment failed to produce complete remission of obsessive compulsive disorder symptoms.

the objective of this trial wis to compare in an randomized open trial format the efficacy of association of clomipramine at maximum dosage of 75mg per day and quetiapine at maximum dosage of 200mg per day with ssri after ssri treatment for 12 weeks failed to produce complete remission of ocd symptoms.

Eligibility criteria:
inclusion criteria: * primary ocd diagnosis according to dsm iv criteria * current symptoms were responsible for significant distress * previous trial of at least 12 weeks with ssri (being at least 8 weeks at maximum tolerated dosage) failed to produce full remission of ocd symptoms exclusion criteria: * presence of clinical or neurological diseases that may be worsen by the medications included in treatment protocol * current substance dependence or abuse, * current psychotic symptoms * current suicide risk * and current pregnancy or intention to get pregnant before the end of the treatment protocol

Keywords: obsessive compulsive disorder pharmacological treatment quetiapine clomipramine ssri
risk factors for early pocd in the patients with psm undergoing crs-hipec

Conditions: Postoperative Cognitive Dysfunction

Summary: objectives to investigate the incidence and associated factors for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy(crs-hipec).methods fifty patients aged 18-65 yr were included in the research and were grouped base on the score of neuropsychological assessments which had done in the ward at 7 day before and after the surgery. the investigators monitored various indicators in the perioperative period, such as age, body weight, sex, education, duration of operation, intraoperative blood loss, cardiovascular events, amount of fluid infused per hour. meanwhile, the concentration of serum amploid a (saa),il-1beta,tnf-alpha,hmgb1,s100b,cortisol and abeta40 were measured at the various stage of the operation and 24 hours after the operation, and the differences of data between postoperative cognitive dysfunction(pocd) and non-pocd groups were analyzed.


Eligibility criteria:
inclusion criteria: * age \ 18 years * the patients with peritoneal surface malignancies willing to undergo the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy exclusion criteria: * age \ 65 years * several organ function severely abnormal and can not tolerate the surgery,such as suffering from severely anemia, liver and renal function disfunction, heart and cerebrovascular disease * cognitive function was assessed by mini-mental state examination (mmse) at 1 day before operation and the score\<23 * people with neurological and psychiatric disease, such as anxiety, senile dementia, stroke sequela, cerebral hemorrhage, etc * psychiatric drug abusers * patients reluctant to go along with the trial

Keywords: peritoneal surface malignancies post operative cognitive dysfunction